0001104659-18-000771.txt : 20180104
0001104659-18-000771.hdr.sgml : 20180104
20180104160708
ACCESSION NUMBER: 0001104659-18-000771
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180102
FILED AS OF DATE: 20180104
DATE AS OF CHANGE: 20180104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaughn Victor
CENTRAL INDEX KEY: 0001567077
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 18510143
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 1550 EAST GUDE DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 1550 E GUDE DR
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 1550 E GUDE DR
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
a4.xml
4
X0306
4
2018-01-02
0
0001356576
SUPERNUS PHARMACEUTICALS INC
SUPN
0001567077
Vaughn Victor
C/O SUPERNUS PHARMACEUTICALS, INC.
1550 EAST GUDE DRIVE
ROCKVILLE
MD
20850
0
1
0
0
Sr. VP of Sales
Common Stock
2018-01-02
4
M
0
55000
7.90
A
64344
D
Common Stock
2018-01-02
4
S
0
55000
40.1147
D
9344
D
Employee Stock Option (Right to Buy)
7.90
2018-01-02
4
M
0
55000
0
D
2023-02-05
Common Stock
55000
30000
D
Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017.
Includes an aggregate of 785 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.0000 to $40.7000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.
/s/ Gregory S. Patrick, as attorney-in-fact
2018-01-04